half-life

Exendin-4 (Exenatide) is a glucagon-like peptide-1 receptor (GLP-1) agonist (IC50: 3.22 nM). Exenatide is a 39 amino acid peptide. Compared to GLP-1, exenatide has a longer half-life of 2.4 hours.

Pegylated synthetic human C-peptide exhibits similar bioactivity to natural C-peptides (non-polyethylene glycolated) and demonstrates an extended plasma half-life, making it suitable for research in diabetic peripheral neuropathy [1].

HPN328 is a humanized trispecific T-cell activating construct (TriTAC) that targets CD3 to engage T cells, targets HSA to extend its half-life, and targets DLL3 on tumor cells. It effectively induces T-cell-mediated cytotoxicity against DLL3-expressing small cell lung cancer (SCLC), leading to tumor regression and sustained antitumor immunity. Molecular weight: 53.06 kDa.

Canvuparatide (MBX 2109) is a prodrug of a parathyroid hormone (PTH) peptide that releases a bioactive PTH[1-32] agonist peptide. This peptide retains a C-terminal fatty acylated lysine (Lys33), which extends the half-life of Canvuparatide. It is utilized in the study of hypoparathyroidism symptoms such as hypocalcemia and hyperphosphatemia.

KYL peptide is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.

Dasiglucagon acetate is a novel glucagon analog for diabetic hypoglycemia therapy. Dasiglucagon acetate has demonstrated established solubility and stability in an aqueous formulation. Pharmacokinetics studies have shown dasiglucagon acetate to exhibit hi

KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.

Pegsebrenatide (NLY01), a long-acting GLP-1R agonist, exhibits an extended half-life and favorable blood-brain barrier penetration. It impedes A1 astrocyte transformation, mitigates dopaminergic cell death, and ameliorates motor symptoms in mouse models of Parkinson's disease (PD) [1].